Genetic Technologies (FRA:DU8) Interest Expense : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Genetic Technologies Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Genetic Technologies's interest expense for the three months ended in Dec. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Genetic Technologies's Operating Income for the three months ended in Dec. 2023 was € 0.00 Mil. Genetic Technologies's Interest Expense for the three months ended in Dec. 2023 was € 0.00 Mil. GuruFocus does not calculate Genetic Technologies's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Genetic Technologies Interest Expense Historical Data

The historical data trend for Genetic Technologies's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Interest Expense Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.04

-0.01

-0.02

Genetic Technologies Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Genetic Technologies Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Genetic Technologies (FRA:DU8) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Genetic Technologies's Interest Expense for the three months ended in Dec. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was €0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €0.05 Mil.

Genetic Technologies's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate Genetic Technologies's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Genetic Technologies Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Genetic Technologies (FRA:DU8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (FRA:DU8) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

GENE:USA DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (FRA:DU8) Headlines

No Headlines